Contact
Please use this form to send email to PR contact of this press release:
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention
TO:
Please use this form to send email to PR contact of this press release:
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention
TO: